Medical News Today -
21 Jan 2014 12:00
Results of a real-world study published in the Primary Care Respiratory Journal have shown that asthma patients may be switched from fluticasone propionate-salmeterol (FP-SAL) to extra-fine beclometasone-formoterol (efBDP-FOR) at an equivalent or lower inhaled corticosteroid (ICS) dosage with no reduction in clinical effectiveness but a significant reduction in cost to the NHS.1The REACH (Real-world Effectiveness in Asthma therapy of Combination inHalers) study investigated the clinical and cost...
Share this Article